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Ancora Cooks with Carbs
Synthesizing Carbohydrate VaccinesIn the 200 years since Edward Jen-
ner showed that immunity to small-
pox could be induced by inoculat-
ing people with cowpox, vaccines
have been the workhorses of public
health. Diseases such as measles,
diphtheria, rubella, and polio are
barely encountered any more in de-
veloped countries.
Traditionally, vaccines have been
made from dead or attenuated path-
ogens, but in some cases where this
approach is unsuitable, an antigen
isolated from the pathogen surface
is used to induce immunity. Most
of the antigens that are selected
are proteins, because in most cases
proteins are the most abundant anti-
gens expressed on the pathogen
surface, and they induce a strong
immune response in humans. But
since antigenic proteins, like all
proteins, are directly encoded by a
gene, any mutation in the gene will
result in a change in the antigen.
When this happens, the resulting
antigen is treated by the immune
system as a new antigen, and any
former immunity will be lost, as in the
cases of the common cold or HIV
viruses. Pathogens such as proto-
zoans that have a complex life cycle
shift their surface proteins (in some
cases, as often as every two weeks)
as they evolve, making it hard for
the immune system to fight them or
for any long-term immunity to be
established or artificially induced.
For these reasons, immunologists
have turned to other antigens that
are less susceptible to change by
mutation and are rarely shifted in the
life cycle of pathogens. Such anti-
gens are complex carbohydrates.
Carbohydrate antigens are synthe-
sized and expressed via pathways
involving at least one enzyme, and,
although the enzyme is subject to
mutation, most nonlethal mutations
result in a functional enzyme. Thus,
the carbohydrate that it builds will
not be altered.
However, carbohydrate antigens
pose certain difficulties. In mostcases, their surface densities are
small, which makes isolating them
from the organism in sufficient quan-
tities unfeasible; most of these anti-
genic carbohydrates are complex
structures of polysaccharide chains
that are tethered to a cell wall pro-
tein or phospholipids. Until recently,
it was difficult to synthesize them,
and to obtain reasonable yields. Fur-
thermore, carbohydrate antigens do
not stimulate the human immune
system as readily as do proteins,
and they need to be conjugated
with an adjuvant to induce immunity,
especially in infants.
Immunologistshaveturned
to other antigens that are
less susceptible to change
by mutation and are rarely
shifted in the life cycle
of pathogens. Such anti-
gens are complex carbo-
hydrates.
For these reasons, even though
research on carbohydrate-based
vaccines at the Rockefeller Univer-
sity was initiated as early as the
1920s, only a few have met with
success. These include vaccines
against Haemophilus influenzae
(HiB), a disease that infects 3 million
people and causes 400,000 to
700,000 deaths annually, particu-
larly of infants aged 4 to 18 months.
The first carbohydrate HiB vaccines
from bacterial isolates were ap-
proved in the U.S. in the mid-1980s
[1]. A completely synthetic version
was approved for use in Cuba in
2004 [2]. Other carbohydrate-based
vaccines, such as MenC, from bac-
terial isolates exist for meningococ-
cal group C (a MenB vaccine is in
phase II trials) to vaccinate against
meningitis, a disease that affects
120,000 people annually, with amortality rate of between 10 and 15
percent. Meningococci and the HiB
pathogen both belong to a family
of bacteria that express a large
amount of polysaccharides on their
cell capsules.
More recent work on synthesis of
complex carbohydrates by Profes-
sor Samuel Danishefsky’s group
at Columbia University and Memo-
rial Sloan-Kettering Cancer Center
(MSKCC) and others has vastly
extended the possibilities for syn-
thesizing complex carbohydrates.
These new synthetic paths may
open new avenues for vaccine de-
velopment. ‘‘I don’t think anyone
says that carbohydrate vaccines in
principle ought to be better than
a peptide vaccine,’’ said Danishef-
sky, ‘‘. the carbohydrate area is
an overlooked area. And it can
be attacked because of major ad-
vances in chemistry.’’
Evasive Action
Leishmaniasis is a disfiguring dis-
ease caused by a protozoan (Leish-
mania), spread by the female sand-
fly, that affects 12 million people
worldwide. Visceral leishmanaisis,
the fatal variant, is estimated to
affect at least 500,000 people annu-
ally. A Leishmania protozoan ex-
presses different protein antigens
as it evolves through its life cycle.
As a result, it is hard for the immune
system to effectively resist the path-
ogen, and conventional vaccines
have failed to induce substantial im-
munity. Malaria is a deadly disease
that is caused by another protozoan
with a complex life cycle for which
no effective vaccine exists to date.
Because the carbohydrate antigens
on the surfaces of these parasites
do not shift as often as the protein
antigens, they are good candidates
on which to base a vaccine.
Dr. Peter H. Seeberger, formerly
a post-doc in the Danishefsky labo-
ratory and now at the Swiss Federal
Institute of Technology (ETH), has
been working for years with
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thetic, carbohydrate-based vac-
cines. His expertise in synthesizing
complex carbohydrates played a
major role in efforts to develop vac-
cines against leishmaniasis and
malaria, both currently in preclinical
stages.
The malaria vaccine, developed in
collaboration with microbiologist
Louis Schofield of the Walter and
Eliza Hall Institute of Medical Re-
search in Australia, blocks the toxins
secreted by the micro-organism. It
does not aim at preventing the dis-
ease, but rather at preventing its
acute symptoms and reducing mor-
tality. Currently it is being tested ‘‘in
higher-order animals,’’ says See-
berger.
This year, Seeberger led a multi-
disciplinary group of chemists and
immunologists from Pevion, a Swiss
biotech, and the Swiss Tropical In-
stitute in Basel that announced
a two-part synthetic vaccine candi-
date for visceral leishmaniasis [3].
Seeberger’s group was responsible
for finding a route for the synthesis
of the complex carbohydrate anti-
gen, the key element in the vaccine.
In order to get a sufficient immune
response, the carbohydrate antigen
was conjugated to the empty shell
of an influenza virus that served as
an adjuvant to stimulate the body’s
immune system.
Ancora’s Carbohydrate Factory
Ancora Pharmaceuticals (www.
ancorapharma.com) was started in
2002 by Seeberger and others to
develop a synthesis platform for
complex carbohydrates after they
won the Massachusetts Institute of
Technology’s 50K entrepreneurial
competition. The company, num-
bering less than ten people, is lo-
cated in Medford, Massachusetts
and occupies space vacated by Ki-
netix and Nanosys. ‘‘Distinguished
predecessors,’’ said John Pena,
PhD, president. According to Pena,
Ancora has a lead candidate to treat
malaria in preclinical studies. Vac-
cine candidates targeted against
leishmaniasis and tuberculosis will
be in preclinical studies by the end
of the year. The company is also
eyeing anticoagulants and vaccines
for autoimmune disorders, as well
as pathogens, such as anthrax,
used in biowarfare. The malaria pro-
gram is funded by a $3.3 millionNational Institutes of Health (NIH)
SBIR grant. The NIH is also provid-
ing support for their tuberculosis
program, and the company has
a round of private investment.
‘‘Ancora has a platform technol-
ogy which we developed in my lab
when I was at still at MIT,’’ said See-
berger. ‘‘This is a way of automated
oligosaccharide synthesis that gives
us access to molecules about 500
times faster than previously. It is
about a day instead of about a year
to a year and a half. Ancora has
also in-house capabilities to make
much larger quantities.’’ According
to Seeberger, although the synthe-
sizer typically makes small quanti-
ties, Ancora can also produce
more, such as tens of grams to kilo-
grams of the malaria vaccine candi-
date.
Seeberger notes that a total labo-
ratory synthesis procedure has to be
completed before scaling up and
automation can be implemented.
Among the many challenges in syn-
thesizing carbohydrates is that the
monomers are complex and can re-
act through many different sites. It
is unclear whether it is possible to
develop an automated, universal
method that would be appropriate
for a large variety of carbohydrates.
The synthetic methodology em-
ployed by Ancora, adopted from au-
tomated synthesis used to manufac-
ture oligonucleotides, enzymes,
peptides, and certain proteins, is to
assemble a library of intermediate
species that serve as building blocks
for many complex carbohydrates
and to combine them to assemble
the desired molecule, rather like
building a prefab house of modular
components. If Ancora can find
a way of automating a substantial
number of key candidates, it will in-
deed be a major achievement.
Vaccines in general, and vaccines
for developing countries, target
a large market, but it is not neces-
sarily a lucrative one. Consequently,
‘‘Ancora has a much broader plat-
form that also does carbohydrate
arrays,’’ Seeberger said. ‘‘The syn-
thesis platform is really the base of
the company. The vaccine applica-
tion is one big application that An-
cora is obviously doing.’’
There is interest from unnamed
large pharmas for the leishmaniasis
vaccine. ‘‘Initially, veterinary vac-
cines may be the way to go,’’ saidSeeberger. ‘‘The tests are relatively
expensive. It is cheaper to test in
dogs. The next step if these veteri-
nary vaccines work well [is to] go
back into humans.’’
Cancer Vaccines
One of the many approaches to
treating cancer is using a vaccine
to induce the immune system to
fight the disease. These vaccines,
in an attempt to avoid recurrence
of the tumor, are aimed predomi-
nantly at people who have under-
gone cancer treatment. Targeting
the patterns of carbohydrate anti-
gens that are overexpressed by
some cancer cells is one promising
strategy. One example is a three-
part cancer vaccine that is in devel-
opment by Professor Geert-Jan
Boons (http://cell.ccrc.uga.edu/
%7egjboons/boons/Home.htm) of
the Complex Carbohydrate Re-
search Center of the University of
Georgia, Athens and uses a peptide
antigen as an adjuvant. Samuel Dan-
ishefsky’s laboratory is also working
on synthetic carbohydrate vaccines
for cancer including Globo-H, a uni-
molecular multivalent candidate
targeting breast cancer. Globo-H
constitutes a single glycopeptide
that contains five different cancer
antigens [4].
Danishefsky is also a cofounder of
Optimer Pharmaceuticals (www.
optimerpharma.com), along with
Dr. Chi-Huey Wong, professor of
chemistry at The Scripps Research
Institute in La Jolla, California and
Michael N. Chang, PhD. The San
Diego company, founded in 1998,
licensed carbohydrate cancer vac-
cines from Danishefsky’s labora-
tory. Optimer streamlines oligosac-
charide synthesis by avoiding the
dreaded chromatography stage of
separation through the develop-
ment of a ‘‘one-pot synthesis’’ to
produce the carbohydrate antigen.
Other carbohydrate cancer vac-
cines in clinical trials are being
developed by New York-based
Progenics Pharmaceuticals (www.
progenics.com) and are currently
part of a multiyear study that was ini-
tiated by MSKCC and carried out
in Europe. Biomira (www.biomira.
com), a 100 person company in
Edmonton, Canada, is currently de-
signing a glycopeptide-based vac-
cine for cancer. ‘‘It is more likely we
can use it for colon cancer or breast
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PhD, vice president and general
manager of the Synthetic Biologics
Unit of Biomira. The work is still in
preclinical stages, but Koganty says
that the results are encouraging.
With the advent of procedures
enabling efficient synthesis of oligo-
saccharides, the development of
carbohydrate vaccines for recalci-
trant infectious and parasite-borne
diseases and various cancers ap-
pears increasingly feasible. ‘‘That
is the vision . a wholly synthetic,
wholly homogeneous vaccine,’’
said Danishefsky. ‘‘If you have that
vision, it has to be made by a total
synthesis. The bad news is that
even with the best methods, total
synthesis is not a trivial undertaking.
But the good news is that you don’t
need much compound. With a gram
you could probably treat New York.’’
It is not such a stretch to imagine
that with a few grams more, one
could treat millions more around
the world.
Selected Reading
1. Centers forDiseaseControl (1990). MMWR
Morb. Mortal. Wkly. Rep. 39, 924–925.
2. Verez-Bencomo, V., Fernandez-Santana,
V., Hardy, E., Toledo, M.E., Rodriguez,
M.C., Heynngnezz, L., Baly, A., Herrera,
L., Izquierdo, M., Villar, A., et al. (2004).
Science 305, 522–525.
3. Liu, X., Siegrist, S., Amacker, M., Zurbri-
gen, R., Pluschke, G., and Seeberger,
P.H. (2006). ACS Chemical Biology 1,
161–164.
4. Keding, S.J., and Danishefsky, S.J.
(2004). Proc. Natl. Acad. Sci. USA 101,
11937–11942.
Wendy Wolfson (wendywolfson@nasw.org)
is a science technology writer based in
Oakland, California.
